NICE recommendation of darolutamide plus hormone therapy for metastatic prostate cancer offers around 6000 patients in ...

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...

An international research team led by the Medical University of Vienna has demonstrated for the first time that thyroid ...

PHILADELPHIA, PA / ACCESS Newswire / October 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a ...

Combining 177 Lu-PSMA-617 with SOC produced statistically significant rPFS, reducing the risk of radiographic progression or death by 28% (HR 0.72; 95% CI, 0.58-0.90) vs SOC alone in patients with ...

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

Scientists have identified two enzymes that help prostate cancer cells grow, survive and resist treatment, paving the way for ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: 4 Clinical-Stage Biotechs to Watch as the Sector Rebounds (MDCX, AUPH, LEXX, EDSA) ...

Want to putt like the pros? Ian Poulter shows how a simple string can improve your putting alignment, eye position and stroke.

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...